文献速递中医内科中药与中成药合理使用

化湿败毒方对比洛匹那韦-利托那韦治疗成人COVID-19的非随机对照试验

Efficacy and safety of Chinese herbal medicine versus Lopinavir-Ritonavir in adult patients with coronavirus disease 2019: A non-randomized controlled trial.
PubMed 文献 · Phytomedicine · 2020-10-08

本研究为非随机对照试验,纳入60例实验室确诊的成人COVID-19患者,分三组各20例:A组洛匹那韦-利托那韦,B组化湿败毒方联合洛匹那韦-利托那韦,C组化湿败毒方(允许中药注射剂)。C组临床缓解时间显著短于A组和B组(5.9天 vs 10.8天,p<0.05;5.9天 vs 9.7天,p<0.05),三组临床缓解率及安全性指标无显著差异。

要点

  • 化湿败毒方组临床缓解时间显著短于洛匹那韦-利托那韦组及联合组。
  • 三组临床缓解率均较高,分别为95.0%、100.0%、100.0%。
  • 三组临床生化指标与安全性指标无显著差异。

核心结论

  • 洛匹那韦-利托那韦对COVID-19有一定疗效,化湿败毒方可能在一定程度上增强该效应。
  • 化湿败毒方联合中药注射剂在治疗COVID-19中显示出优势。

研究设计与样本

  • 2020年1月30日至3月23日在武汉开展的非随机对照试验,纳入60例实验室确诊的成人COVID-19患者,每组20例。

主要发现

  • A、B、C三组临床缓解率分别为95.0%(19/20)、100.0%(20/20)、100.0%(20/20)。
  • C组临床缓解时间显著短于A组(5.9天 vs 10.8天,p<0.05)和B组(5.9天 vs 9.7天,p<0.05)。
  • 三组解除隔离时间无显著差异,临床生化指标与安全性指标无显著差异。

关键数值与推荐

  • 主要结局为临床缓解时间(入院至首次新冠病毒检测阴性或胸部CT明显改善的间隔)和临床缓解率(临床时间在16天内的患者数/总患者数)。

临床怎么用

  • 成人COVID-19患者可考虑使用化湿败毒方,或联合中药注射剂,以缩短临床缓解时间。
  • 化湿败毒方联合洛匹那韦-利托那韦未显示比单用化湿败毒方更优的临床缓解时间。

局限性

  • 为非随机对照试验,样本量较小(每组20例),结论需前瞻性双盲随机对照试验证实。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Treatments for coronavirus disease 2019 (COVID-19) are limited by suboptimal efficacy. METHODS: From January 30, 2020 to March 23, 2020, we conducted a non-randomised controlled trial, in which all adult patients with laboratory-confirmed COVID-19 were assigned to three groups non-randomly and given supportive treatments: Group A, Lopinavir-Ritonavir; Group B, Huashi Baidu Formula (a Chinese medicineformula made by the China Academy of Chinese Medical Sciences to treat COVID-19, which is now in the clinical trial period) and Lopinavir-Ritonavir; and Group C, Huashi Baidu Formula. The use of antibiotics, antiviruses, and corticosteroids was permitted in Group A and B. Traditional Chinese medicine injections were permitted in Group C. The primary outcomes were clinical remission time (interval from admission to the first time the patient tested negatively for novel coronavirus or an obvious improvement was observed from chest CT) and clinical remission rate (number of patients whose clinical time was within 16 days/total number of patients). RESULTS: A total of 60 adult patients with COVID-19 were enrolled at sites in Wuhan, China, and the sample size of each group was 20. In Groups A, B and C, the clinical remission rates were 95.0%%(19/20), 100.0%%(20/20) and 100.0%%(20/20), respectively. Compared with Groups A and B, the clinical remission time of Group C was significantly shorter (5.9 days vs. 10.8 days, p < 0.05; 5.9 days vs. 9.7 days, p < 0.05). There was no significant difference among Groups A, B, and C in terms of the time taken to be released from quarantine. The clinical biochemical indicators and safety indexes showed no significant differences among the three groups. CONCLUSIONS: Our findings suggest that Lopinavir-Ritonavir has some efficacy in the treatment of COVID-19, and the Huashi Baidu Formula might enhance this effect to an extent. In addition, superiority was displayed in the treatment of COVID-19 through a combination of the Huashi Baidu Formula and traditional Chinese medicine injection. In future, well-designed prospective double-blinded randomised control trials are required to confirm our findings.

来源:Phytomedicine,查看原文。版权归原作者所有。

引用

  1. Shi N, Guo L, Liu B, et al. Efficacy and safety of Chinese herbal medicine versus Lopinavir-Ritonavir in adult patients with coronavirus disease 2019: A non-randomized controlled trial. Phytomedicine. 2020. PMID: 33260064. doi:10.1016/j.phymed.2020.153367

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。